Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. weekly Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E12.90 EPS (ttm)5.85 Insider Own0.40% Shs Outstand1.31B Perf Week2.90%
Market Cap98.87B Forward P/E11.46 EPS next Y6.59 Insider Trans-6.11% Shs Float1.29B Perf Month2.29%
Income7.69B PEG- EPS next Q1.61 Inst Own81.00% Short Float1.05% Perf Quarter6.25%
Sales23.20B P/S4.26 EPS this Y-22.80% Inst Trans0.29% Short Ratio2.16 Perf Half Y3.67%
Book/sh16.70 P/B4.52 EPS next Y0.00% ROA3.30% Target Price87.87 Perf Year-8.61%
Cash/sh19.79 P/C3.82 EPS next 5Y-5.54% ROE10.10% 52W Range64.27 - 89.54 Perf YTD5.40%
Dividend2.28 P/FCF17.74 EPS past 5Y36.20% ROI19.90% 52W High-15.67% Beta1.04
Dividend %3.02% Quick Ratio2.90 Sales past 5Y21.90% Gross Margin80.70% 52W Low17.49% ATR1.38
Employees10000 Current Ratio3.00 Sales Q/Q-20.90% Oper. Margin45.40% RSI (14)54.59 Volatility1.66% 1.66%
OptionableYes Debt/Eq1.34 EPS Q/Q-40.80% Profit Margin9.50% Rel Volume1.52 Prev Close74.83
ShortableYes LT Debt/Eq1.20 EarningsOct 24 AMC Payout128.20% Avg Volume6.26M Price75.51
Recom2.10 SMA202.07% SMA50-0.18% SMA2000.67% Volume9,526,953 Change0.91%
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Sep-22-18 12:35AM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
Sep-21-18 06:12PM  FDA Confirms Positive Safety Profile of Acadia's Nuplazid Zacks
03:23PM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
12:00AM  How Do Drugs Compete Against Each Other? Motley Fool
Sep-20-18 04:23PM  Study shows PrEP effective at stopping HIV infections American City Business Journals
03:53PM  Curing AIDS: After antiretrovirals brought the disease under control, a more ambitious goal is now in sight American City Business Journals
03:49PM  Ultragenyx's Shares Surge More Than 80% in the Year So Far Zacks
11:40AM  Molecular Templates Surges 50%, Inks Cancer Deal With Takeda Zacks
07:32AM  The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences Zacks
Sep-19-18 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
02:07PM  Gilead Faces Doubts on Wall Street a Year After $12 Billion Deal Bloomberg
11:01AM  Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success Zacks
10:13AM  Viking Therapeutics Liver Candidate Passes Test, Shares Soar Zacks
09:30AM  Is Gilead (GILD) a Suitable Stock for Value Investors Now? Zacks
07:45AM  UK rejects adult Novartis CAR-T therapy, after 'yes' in kids Reuters
05:30AM  UK rejects adult Novartis CAR-T therapy, after 'yes' in kids Reuters
05:05AM  UK rejects adult Novartis CAR-T therapy, after 'yes' in kids Reuters
Sep-18-18 06:18PM  Agenus Receives Milestone Payment of $5 Million from Incyte Zacks
03:00PM  Viking Therapeutics and Madrigal Pharmaceuticals Are Racing to the Finish Line in NASH Motley Fool
Sep-17-18 06:13PM  3 High-Quality Biotech Companies for 4th Quarter GuruFocus.com
05:42PM  Health Care Digest: UCSF's ImmunoX revolution, Gilead's deal, a pain breakthrough and more American City Business Journals
02:33PM  Why Gilead Stock Is a Sleepy Giant Waiting to Break Out InvestorPlace
10:03AM  This cancer-fighting biotech sped from startup to IPO filing in 10 months American City Business Journals
09:30AM  Should Value Investors Pick Gilead Sciences (GILD) Stock? Zacks
Sep-14-18 09:53AM  Unity (UBX) Catches Eye: Stock Jumps 8.8% Zacks
07:00AM  Gilead taps Durham gene editing firm for $445M deal American City Business Journals
06:15AM  A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis Motley Fool
Sep-13-18 03:48PM  How Gilead Call Prices Tripled Overnight TheStreet.com
03:07PM  Gilead taps Durham gene editing firm for $445M deal American City Business Journals
11:18AM  Gilead Inks Gene Editing Collaboration Deal for HBV Infection Zacks
10:34AM  Company News For Sep 13, 2018 Zacks
08:53AM  Better Buy: Gilead Sciences, Inc. vs. Biogen Motley Fool
06:31AM  What's Next for Gilead Sciences After Its Latest Clinical Success Motley Fool
Sep-12-18 03:40PM  Gilead's Rheumatoid Arthritis Drug Successful in Phase III Zacks
12:46PM  Here's Why Galapagos NV Is Skyrocketing 18.3% Today Motley Fool
11:31AM  Stocks - Apple Gains in Pre-market; Facebook, Google Fall; Nielsen Jumps Investing.com
11:03AM  Galapagos, Gilead bask in $4-6 billion new drug sales hope Reuters
10:41AM  Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars Zacks
10:26AM  US STOCKS-Tech stocks weigh on Wall St, energy stocks help cut losses Reuters
09:55AM  Merck's Antibacterial Drug Succeeds in Label Expansion Study Zacks
09:43AM  Stocks Open Mixed As Chips Weigh, Oil Rises, But This Pot Stock Soars Investor's Business Daily
09:17AM  3 Top Stocks for Investing in Pharma's Next $35 Billion Market Motley Fool
09:11AM  Incyte, Foundation Medicine Partner for Companion Diagnostics Zacks
09:00AM  US STOCKS-Wall St to open flat as trade worries linger; Apple event in focus Reuters
08:31AM  Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing Business Wire
08:26AM  The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Gilead Sciences and Exelixis ACCESSWIRE
07:49AM  US STOCKS-Futures flat as trade worries linger; Apple event in focus Reuters
07:39AM  Stocks making the biggest move premarket: AAPL, NIO, GILD, TEVA, BMY & more CNBC
07:00AM  [$$] Stocks to Watch: Apple, Goldman Sachs, Alphabet The Wall Street Journal
06:00AM  Gilead Sciences Reports Market-Moving News Motley Fool
Sep-11-18 04:28PM  Drug succeeds in arthritis study, Gilead stock jumps MarketWatch
04:07PM  GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS GlobeNewswire
04:05PM  Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis Business Wire
11:37AM  Endocyte Announces FDA's Acceptance of Trial Endpoint Change Zacks
Sep-10-18 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
05:00PM  Shire's ADHD Portfolio Remains Strong Amid Competition Zacks
07:20AM  The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE Zacks
Sep-09-18 10:39AM  Only 3 Days Left Before Gilead Sciences Inc (NASDAQ:GILD) Will Be Trading Ex-Dividend, Simply Wall St.
Sep-07-18 04:15PM  Top Research Reports for Abbott, Gilead & FedEx Zacks
02:10PM  Arrowhead Stock Is Not Done Rallying After Its 38% Jump InvestorPlace
12:55PM  Midterm Elections Offer Promise and Peril Barrons.com
07:50AM  Dont Gamble on Biotech! Industry Comps & Smart Investors Indicate Why You Could Generate Big Returns on This Unknown Stock ACCESSWIRE
Sep-06-18 03:36PM  bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy Zacks
03:25PM  Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint Zacks
08:28AM  The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data Benzinga
06:30AM  3 Top Big Pharma Stocks to Buy Now Motley Fool
01:02AM  GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT GlobeNewswire
01:00AM  Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint Business Wire
Sep-05-18 06:50PM  Top 5 Biotech Stocks for 2018 Investopedia
05:34PM  Horizon Pharma Completes Enrollment in Eye Disease Study Zacks
05:15PM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
04:40PM  Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout Zacks
11:12AM  MannKind Stock Up on Licensing Deal With United Therapeutics Zacks
06:00AM  Our Ultimate Stock-Pickers' Top 10 Buys and Sells Morningstar
04:21AM  UK deal makes Novartis cancer cell therapy available to kids Reuters
Sep-04-18 04:05PM  Gilead Enters Licensing Agreement With Trianni for Use of Trianni Transgenic Human Monoclonal Antibody Discovery Platform Business Wire
08:00AM  Is Now a Good Time to Buy Gilead Sciences? Motley Fool
Sep-03-18 09:40AM  AstraZeneca's Lupus Drug Misses Primary Endpoint in Study Zacks
Sep-02-18 06:35AM  Better Buy: Amgen Inc. vs. Gilead Sciences, Inc. Motley Fool
Aug-31-18 04:19PM  Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A Zacks
04:05PM  Alnylam Gets European Nod for First-Ever RNAi Therapeutic Zacks
11:34AM  Vertex Inks Deal With Genomics to Make Serious Disease Drugs Zacks
Aug-30-18 06:35PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
04:01PM  Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12 Business Wire
03:41PM  Affimed (AFMD) Surges on Collaboration Contract with Roche (revised) Zacks
09:50AM  Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data Zacks
Aug-29-18 05:12PM  Time to Take Some Profits in Sarepta Therapeutics Stock InvestorPlace
01:05PM  Is Gilead Sciences Inc (NASDAQ:GILD) Attractive At Its Current PE Ratio? Simply Wall St.
11:20AM  Affimed (AFMD) Surges On Collaboration Contract With Roche Zacks
09:38AM  Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA Zacks
09:14AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Aug-28-18 08:00PM  3 Top Healthcare Stocks to Buy This Week Motley Fool
05:45PM  Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval Zacks
05:00PM  Gilead Sciences Appoints Laura Hamill as Executive Vice President, Worldwide Commercial Operations Business Wire
01:57PM  [$$] U.K. Nixes Gilead Gene Therapy Citing Cost The Wall Street Journal
11:39AM  Amgen Files for Once-Weekly Regimen for Myeloma Drug Kyprolis Zacks
11:16AM  Gilead's CAR-T Therapy Yescarta Gets Approval in Europe Zacks
07:05AM  UK rejects Gilead's CAR-T cancer cell therapy as too expensive Reuters
Aug-27-18 06:34AM  Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy Business Wire
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM